The objective of this study is to determine if early high volume intravenous fluid administration (hyperhydration) may be effective in mitigating or preventing…

Shiga Toxin-Producing Escherichia Coli (E. Coli) InfectionHemolytic-Uremic Syndrome

~Estimated

~$10 – $6,250

University of CalgaryNCT05219110

An Observational, Non-Interventional, Multi-Center, Multi-National Study of Patients With Atypical Hemolytic-Uremic Syndrome (aHUS Registry)

Post-marketing safety data on patients treated and untreated with eculizumab or ravulizumab.

Atypical Hemolytic-Uremic Syndrome

~Estimated

~$10 – $1,050

Alexion Pharmaceuticals, Inc.NCT01522183